Mesoblast Stock Forecast, Price & News

-0.06 (-0.67 %)
(As of 04/16/2021 12:00 AM ET)
Today's Range
Now: $8.94
50-Day Range
MA: $8.94
52-Week Range
Now: $8.94
Volume74,656 shs
Average Volume589,567 shs
Market Capitalization$1.16 billion
P/E RatioN/A
Dividend YieldN/A
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, diabetic kidney diseases, and type 2 diabetic nephropathy. It operates in the United States, Australia, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develop and commercialize cell therapy for the treatment of chronic low back pain. The company was founded in 2004 and is headquartered in Melbourne, Australia.
Mesoblast logo

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:MESO
Previous SymbolOTCMKTS:MBLTY
Year FoundedN/A



Sales & Book Value

Annual Sales$32.16 million
Book Value$4.70 per share


Net Income$-77,940,000.00
Net Margins-591.00%


Market Cap$1.16 billion
Next Earnings Date5/26/2021 (Estimated)


Mesoblast (NASDAQ:MESO) Lifted to "Buy" at Maxim Group
April 13, 2021 |
Mesoblast (NASDAQ:MESO) Shares Gap Up to $8.56
April 9, 2021 |
Mesoblast (NASDAQ:MESO) Raised to "Buy" at Maxim Group
April 7, 2021 |
See More Headlines


Overall MarketRank

1.38 out of 5 stars

Medical Sector

696th out of 2,025 stocks

Biological Products, Except Diagnostic Industry

96th out of 177 stocks

Analyst Opinion: 3.2Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
-0.06 (-0.67 %)
(As of 04/16/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MESO News and Ratings via Email

Sign-up to receive the latest news and ratings for MESO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Mesoblast (NASDAQ:MESO) Frequently Asked Questions

Is Mesoblast a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Mesoblast in the last year. There are currently 1 sell rating, 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Mesoblast stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MESO, but not buy additional shares or sell existing shares.
View analyst ratings for Mesoblast
or view top-rated stocks.

What stocks does MarketBeat like better than Mesoblast?

Wall Street analysts have given Mesoblast a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Mesoblast wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Mesoblast?

Mesoblast saw a decrease in short interest in March. As of March 31st, there was short interest totaling 1,200,000 shares, a decrease of 18.9% from the March 15th total of 1,480,000 shares. Based on an average trading volume of 602,300 shares, the days-to-cover ratio is currently 2.0 days.
View Mesoblast's Short Interest

When is Mesoblast's next earnings date?

Mesoblast is scheduled to release its next quarterly earnings announcement on Wednesday, May 26th 2021.
View our earnings forecast for Mesoblast

How were Mesoblast's earnings last quarter?

Mesoblast Limited (NASDAQ:MESO) announced its quarterly earnings data on Tuesday, March, 2nd. The company reported ($0.22) EPS for the quarter, missing the Zacks' consensus estimate of ($0.10) by $0.12. The company earned $2.24 million during the quarter, compared to analyst estimates of $2.14 million. Mesoblast had a negative net margin of 591.00% and a negative trailing twelve-month return on equity of 18.69%.
View Mesoblast's earnings history

How has Mesoblast's stock price been impacted by Coronavirus (COVID-19)?

Mesoblast's stock was trading at $6.0250 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, MESO stock has increased by 48.4% and is now trading at $8.94.
View which stocks have been most impacted by COVID-19

What price target have analysts set for MESO?

6 equities research analysts have issued 1-year target prices for Mesoblast's shares. Their forecasts range from $7.50 to $20.00. On average, they anticipate Mesoblast's share price to reach $14.55 in the next year. This suggests a possible upside of 62.8% from the stock's current price.
View analysts' price targets for Mesoblast
or view top-rated stocks among Wall Street analysts.

Who are Mesoblast's key executives?

Mesoblast's management team includes the following people:
  • Dr. Silviu Itescu, Founder, CEO, MD, Chairman of Scientific Advisory Board & Exec. Director (Age 64, Pay $1.28M)
  • Mr. Josh Muntner BFA, M.B.A., Chief Financial Officer (Age 52, Pay $713k)
  • Mr. Peter T. Howard B.Sc., L.L.B., BSc, LLB (Hons), Gen. Counsel & Corp. Exec. (Age 53)
  • Mr. Michael Schuster M.B.A., MS, BSc, MBA, Head of Pharma Partnering (Age 44)
  • Dr. Eric Strati M.B.A., Ph.D., Pharm.D., MBA, Sr. VP of Commercial
  • Dr. Fred Grossman, Chief Medical Officer
  • Ms. Dagmar Rosa-Bjorkeson M.B.A., M.S., Chief Operating Officer (Age 57)
  • Sir Jonathan Richard Symonds CBE, BA, FCA, Head of Corp. Fin. & Strategy (Age 62)
  • Mr. Roger D. Brown BA, Head of Spinal Orthopedic Disorders
  • Dr. Paul J. Simmons BSc, Ph.D., Head of Research & New Product Devel. (Age 62)

Who are some of Mesoblast's key competitors?

What other stocks do shareholders of Mesoblast own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mesoblast investors own include Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Exelixis (EXEL), CRISPR Therapeutics (CRSP), Novavax (NVAX), Micron Technology (MU), Vaxart (VXRT) and AbbVie (ABBV).

When did Mesoblast IPO?

(MESO) raised $69 million in an initial public offering (IPO) on Friday, November 13th 2015. The company issued 5,700,000 shares at a price of $12.10 per share. J.P. Morgan and Credit Suisse served as the underwriters for the IPO and Maxim Group and Ladenburg Thalmann were co-managers.

What is Mesoblast's stock symbol?

Mesoblast trades on the NASDAQ under the ticker symbol "MESO."

Who are Mesoblast's major shareholders?

Mesoblast's stock is owned by a number of retail and institutional investors. Top institutional investors include Penbrook Management LLC (0.19%).

Which major investors are buying Mesoblast stock?

MESO stock was purchased by a variety of institutional investors in the last quarter, including Penbrook Management LLC.

How do I buy shares of Mesoblast?

Shares of MESO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Mesoblast's stock price today?

One share of MESO stock can currently be purchased for approximately $8.94.

How much money does Mesoblast make?

Mesoblast has a market capitalization of $1.16 billion and generates $32.16 million in revenue each year. The company earns $-77,940,000.00 in net income (profit) each year or ($0.74) on an earnings per share basis.

How many employees does Mesoblast have?

Mesoblast employs 102 workers across the globe.

What is Mesoblast's official website?

The official website for Mesoblast is

Where are Mesoblast's headquarters?

Mesoblast is headquartered at LEVEL 38 55 COLLINS STREET, MELBOURNE C3, 3000.

How can I contact Mesoblast?

Mesoblast's mailing address is LEVEL 38 55 COLLINS STREET, MELBOURNE C3, 3000. The company can be reached via phone at 61-3-9639-6036 or via email at [email protected]

This page was last updated on 4/17/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.